NCT01587534 is a Phase 2 clinical trial of Norzyme in Pancreatic Cancer, sponsored by National Cancer Center, Korea.

Who is sponsoring NCT01587534?

NCT01587534 is sponsored by National Cancer Center, Korea.

What drugs are being tested in NCT01587534?

Interventions in NCT01587534: Norzyme.

What condition does NCT01587534 study?

NCT01587534 studies Pancreatic Cancer.

Is NCT01587534 still recruiting?

NCT01587534 is currently completed. Last updated 13 April 2015.

Last reviewed 2015-04-13 · How we verify

NCT01587534

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase 2 Study of Randomized Controlled Trial of Pancreatic Enzyme Supplementation in Patients With Unresectable Pancreatic Cancer

Completed Phase 2 Last updated 13 April 2015

What this trial tests

Phase 2 trial testing Norzyme in Pancreatic Cancer in 67 participants. Completed in 1 December 2014.

Timeline

1 October 2011

Primary endpoint
1 December 2014

1 December 2014

Quick facts

Lead sponsor	National Cancer Center, Korea
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	67
Start date	1 October 2011
Primary completion	1 December 2014
Estimated completion	1 December 2014
Sites	1 location across South Korea

Drugs / interventions tested

Norzyme — full drug profile →

Conditions studied

Pancreatic Cancer — all drugs for Pancreatic Cancer →

Sponsor

National Cancer Center, Korea

Who can join

18 and older, any sex, with Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

the change in body weight at eight weeks after the randomisation
Time frame: at baseline and 4, 8 week, 24 week
the percentage change in body weight at eight weeks after the randomisation

Sponsor's own description

The investigators planned a prospective, randomized, placebo controlled trial to test the hypothesis that weight loss in patients with unresectable pancreatic cancer with occlusion of the pancreatic duct can be reduced or prevented by pancreatic enzyme replacement therapy in combination with dietary counseling.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Efficacy of pancreatic exocrine replacement therapy for patients with unresectable pancreatic cancer in a randomized trial.
Woo SM, Joo J, Kim SY, Park SJ, et al · · 2016 · cited 37× · PMID 27618657 · DOI 10.1016/j.pan.2016.09.001

Verify or expand the search:

Other recruiting trials for Pancreatic Cancer

Currently open trials in the same condition.

NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting
NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
NCT07236177 — B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosi · EARLY_PHASE1 · recruiting

Other National Cancer Center, Korea trials

Trials by the same sponsor.

NCT07399561 — Effect of Exercise on Chemotherapy-Induced Peripheral Neuropathy · NA · not yet recruiting
NCT07121478 — Patients With High-grade Pancreatic Neuroendocrine Tumors · Phase 2 · enrolling by invitation
NCT07171528 — Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer · Phase 2 · recruiting
NCT07125924 — Intravesical Hyaluronic Acid (HA) for Preventing Radiation Cystitis on Bladder Cancer · NA · not yet recruiting
NCT07041515 — Knowledge-enhanced Digital Intervention to Prevent Low Anterior Resection Syndrome · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01587534 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Cancer Center, Korea
Last refreshed: 13 April 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01587534.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing